A b s t r a c t
Tissue microarray analysis (TMA) allows multiple analyses on multiple patients on sections from a single paraffin block. Although it is widely used in
Tissue microarray analysis [1] [2] [3] (TMA) is a laboratory procedure whereby core samples are taken from the paraffinembedded tissue specimens of multiple patients and transferred to a single multicore paraffin block. This approach allows multiple analyses on multiple patients to be performed on sections from a single paraffin block. Since its introduction in 1998, 1 the process has been used in research and quality assurance studies, with more than 800 references in the current literature. However, to date, only 3 references have been found reporting the use of TMA in clinical practice. [4] [5] [6] TMA has the potential to provide high-volume, standardized, quality-assured testing and more efficient use of patient biopsy material, laboratory reagents, and technical staff time. 2 Quality control material can be routinely built into each TMA block. TMA allows the preservation of the patient's archival tissue for future studies as new biomarkers become available and should allow cost-effective high-volume gene assessment by in situ hybridization methods on all tumors. 3, 7, 8 About 200 breast biomarker tests are conducted per month at the British Columbia Cancer Agency (BCCA) laboratory, Vancouver, Canada. Many of the tissue blocks used for this testing originate from community ("host") hospitals in the province of British Columbia. The test panel includes immunohistochemical analysis for the expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2 (HER2) on all invasive carcinomas. HER2 gene expression analysis by fluorescent in situ hybridization (FISH) is performed on cases that are equivocal for HER2 protein overexpression by immunohistochemical analysis.
This article reports the validation phase of the clinical application of the TMA method in the BCCA laboratory. The study objectives were to examine the performance of the TMA method compared with the whole section method for ER, PR, and HER2 on clinical specimens in the daily laboratory workflow and how to interpret the TMA immunohistochemical results such that the whole section and TMA methods yielded the highest level of agreement.
Specifically the evaluation assessed the following: (1) percentage of routine cases with sufficient tumor for coring for TMA; (2) percentage of TMA cores unsatisfactory for biomarker assessment, therefore requiring whole section testing; (3) interobserver variation in interpretation of immunohistochemical staining on TMA; (4) best interpretation method of immunohistochemical results on TMA scores; (5) the number of cores necessary to ensure accuracy; (6) concordance of immunohistochemical-whole section results with immunohistochemical-TMA results; (7) concordance of FISH-whole section results with FISH-TMA results; and (8) comparative assessment of the cost of the 2 methods.
Materials and Methods

Case Collection and Array Construction
During the study, routine breast biomarker assessment was continued using whole sections. For each case, an initial H&E-stained control section was reviewed to confirm that adequate tissue was in the donor block for transfer to the TMA block and to select and mark the location points for cores to be taken. All blocks submitted for biomarker testing were tissues fixed in 10% neutral buffered formalin. The duration of fixation was not recorded.
Paraffin tissue donor blocks suitable for inclusion in the TMA were collected for 5 days, and the array was built on day 6. Trained technologists using a stereomicroscope and the Beecher TMA instrument (Beecher Instruments, Sun Prairie, WI) removed 4 cores of 0.6 mm from donor blocks and transferred them to a recipient block. Cores were arranged in sectors, each containing 7 rows with 12 cores (3 cases) per row. This array design would allow up to 4 sectors with 21 specimens each. Positive and negative control samples and orientation cores (muscle tissue) were included in each array. TMA sections from the same specimens were stained once weekly using the same staining protocol as for whole sections.
Arrays constructed in the first 3 weeks (TMAs 1-3) were initial pilot arrays used to establish the method. TMAs 4 through 18 were constructed sequentially, once weekly in the laboratory.
The criteria used to accept donor blocks for inclusion in the TMA were as follows: (1) The H&E-stained slide had a minimum of 1 low-power field (8 mm 2 ) of invasive carcinoma. (2) It was possible to remove four 0.6-mm cores and leave diagnostic material remaining in the block. The criteria used to reject blocks from the TMA study were as follows: (1) Consent to core the block had not been obtained from the host hospital. (Permission to core blocks was obtained from 16 of 27 referring host hospitals.) (2) The specimens were core biopsy specimens. (Core biopsy specimens can be used to construct TMA, but this was not investigated in the present study.) (3) The specimens were small biopsy specimens with insufficient invasive carcinoma (<1 low-power field of invasive carcinoma). (4) There was no invasive tumor on the control section. (5) Only microinvasive carcinoma was present.
Biomarker Stains
A variety of ER, PR, and HER2 antibodies were used in this study because the Ventana staining system (Ventana, Tucson, AZ) was introduced into the laboratory to replace a DAKO system (DAKO, Carpinteria, CA) during the study interval. DAKO ER and PR antibodies on TMAs 1 through 5 were stained using a DAKO stainer and on TMAs 6 and 7 using a Ventana Benchmark XT platform. For TMAs 8 through 18, Ventana ER and PR antibodies were used on the Ventana platform.
For HER2, throughout the study, staining was carried out with the DAKO A0485 antibody and the Novocastra Tab250 antibody (Novocastra, Newcastle upon Tyne, England) on the DAKO instrument, the initial method in use at the time of the study, and the Ventana 4B5 antibody (VHER) using the Ventana platform.
It became apparent during the study that the initial protocol for the VHER was too sensitive (false-positives were noted compared with FISH; data not shown). However, to minimize study variables, it was decided to continue to use the initial staining protocol for the Ventana antibody throughout the study despite the oversensitivity of the antibody titration.
Immunohistochemical Scoring of Array and Whole Section Slides
Immunohistochemical stains on whole sections were interpreted by staff pathologists who recorded the mean stain intensity (0-3) and estimated the proportion of invasive tumor stained (0.0-1.0). (The proportion was used to derive a quintile number, similar to that used in the Allred score, as follows: 0 = 0.0, 1 = >0.0-0.1; 2 = >0.1-0.2, 3 = >0.2-0.4, 4 = >0.4-0.6, and 5 = >0.6-1.0.) To assess interobserver variability, TMAs 1 through 7 were each independently interpreted for ER, PR, and HER2 by 3 study pathologists (T.A.T., C.Z., and B.K.). The remainder of the arrays were interpreted by one of the study pathologists (T.A.T.). For each core, the maximum stain intensity (0-3) and the estimated portion of tumor cells stained (0.0-1.0) were recorded.
All cases interpreted as equivocal for HER2 protein overexpression on the whole sections were sent for HER2 gene expression analysis using FISH. Results for antibodies A0485 (A) and Tab250 (T) were combined to produce an AT intensity "score" (eg, A0485 = 0; Tab250 = 1; AT score = 01). AT scores of 00, 01, and 10 were considered negative for protein overexpression; scores of 11, 12, 21, 13, 31, and 22 as equivocal; and scores of 23, 32, and 33 as positive. For the Ventana antibody (VHER) the immunohistochemical results were considered negative for protein overexpression with scores of 0 or 1, equivocal with a score of 2, and positive with a score of 3. The criteria are summarized in ❚Table 1❚.
Fluorescence In Situ Hybridization
Testing for HER2 gene amplification was performed using FISH analyses with the Vysis PathVysion HER2 kit (Vysis, Des Plaines, IL). FISH results on whole sections were scored by counting the number of HER2 and Cep17 signals in 40 whole nuclei and calculating an HER2/Cep17 ratio. Whole section FISH slides were scored by a technologist, and the result was verified by a pathologist (T.A.T., C.Z., and B.K.).
Statistical Analysis
Interobserver variability in interpretation of immunohistochemical stains on TMA was examined by testing for difference among the concordance between the immunohistochemical analysis-whole section intensity score and the maximum of the immunohistochemical analysis-TMA intensity score reported by each pathologist, using the χ 2 test at the .05 level of significance. The comparison of the performance of the TMA and whole section methods and the method of interpretation for the TMA immunohistochemical results, which yield the highest level of agreement, are examined through the concordance between the whole section and TMA results of one randomly chosen pathologist.
Results
Total Cases Analyzed
A total of 18 TMAs were constructed for this study. TMAs 1 through 3 (76 samples) were considered "pilot arrays," and, thus, the results were not included in the array performance analysis but were included in the concordance and interobserver variability analyses. TMAs 4 through 18 were constructed weekly during a 4-month period in which 639 samples for breast biomarkers were submitted to the laboratory. Consent for TMA was not given for 122 of the samples, leaving 517 cases potentially eligible for TMA. Of these 517 cases, 282 samples (54.5%) were rejected as unsuitable for analysis by TMA ❚Table 2❚. The remaining 235 blocks (45.5%) were suitable for coring and were included in TMAs 4 through 18. These 235 blocks were all excision biopsy specimens with sufficient invasive tumor by the study criteria.
Core Loss and Noninformative Cores
Overall, the arrays had few lost or noninformative (no tumor) cores. As an example, the results for the Ventana HER2 arrays are summarized in ❚Table 3❚. (There was essentially no difference noted in the array performance of other antibodies.) Of 235 cases, 24.3% had at least 1 core that was noninformative owing to core loss (5.5%) or no tumor in the core (18.7%). Of the cases, 8.1% were noninformative in 2 or more cores, most often a result of no tumor in the core section (6.8%).
Interobserver Variability (TMAs 1-7 Only)
Because the intent of the study was to assess the clinical application of TMA, an assessment of interobserver variability in core interpretation was undertaken on arrays 1 through 7 to exclude this as a significant variable. As noted in ❚Table 4❚, there was no statistical difference in core interpretation of stain intensity by 3 pathologists with the exception of ER when assessed at 4 levels of intensity (0-3). However, when ER was assessed at the more clinically relevant division of positive vs negative ❚Table 5❚, no significant difference was noted between observers.
Interpreting Immunohistochemical Results on TMA Cores
There were 4 interpretation methods that were assessed to evaluate the 4 cores from each case: (1) the maximum stain intensity of any nucleus (ER and PR) or cell membrane (HER2) in any 1 of the 4 cores; (2) the mean stain intensity of all cores taken together; (3) the maximum portion of stained cells alone expressed as a quintile number of the 4 cores; and (4) the mean of the "score," which consists of a value derived from the maximum stain intensity plus the quintile number of the 4 cores.
In comparing the concordance between whole section and TMA for the 4 options, the maximum stain intensity in 1 of the 4 cores gave the best concordance for all antibodies ❚Table 6❚. Data analysis for the remainder of the study was, therefore, based on interpreting the maximum stain intensity in the cores, with the maximum stain intensity in any 1 of the 4 cores the result for any given case. 
Number of Cores: Concordance Between Whole Section and TMA
This study used a 4-core per case TMA. To assess the impact of analysis of fewer cores, the data were reanalyzed using a random selection of 3 or 2 of the TMA cores in each case. The results, as shown in ❚Table 7❚, indicate a slight but not statistically significant decrease in concordance with fewer cores analyzed. This suggests that TMA data from 2 cores could be as reliable as the data from 4 cores.
Concordance of Immunohistochemical Staining-Whole Section Results With Immunohistochemical-TMA Results
For all antibodies, the same staining protocol was used for whole section and TMA slides. ER and PR concordance between whole section and TMA was high (Table 7 , 4 cores column). Concordance was 99.2% with the DAKO ER antibody and 97.7% with the Ventana ER antibody. Concordance was 95.0% with the DAKO PR antibody and 89.8% with the Ventana PR antibody. For HER2, concordance between whole section and TMA using the DAKO A0485 antibody was 93.4% but only 82.8% for Zymed Tab250 and 76.6% for the Ventana 4B5 antibody. This weak concordance with the monoclonal HER2 antibodies, Tab250, and Ventana 4B5 indicated that the staining protocol used for whole sections would need to be modified for the TMA sections for these antibodies. To minimize the number of variables in the study, it was decided not to undertake this protocol adjustment during this study interval. However, this adjustment was implemented after completion of the study and before clinical implementation. With protocol adjustment, concordance of 98% was obtained between TMA and whole section and FISH.
Cost Assessment
In our laboratory at the time of this study, the cost of a panel of 3 biomarker antibodies (labor and materials) was $95.00 Canadian (CAD) ❚Table 8❚. The cost of producing and interpreting a single sector array with 18 cases was $255.00 CAD, in other words, approximately $14.00 CAD per case ❚Table 9❚. The apparent cost savings of TMA vs whole section staining by comparing a 1-sector TMA of 18 cases, which costs $255.00 CAD, vs 18 whole sections of the same cases, 
Discussion
This study compared breast biomarker analysis of 4 core samples from breast tumor blocks embedded in a multicase TMA with whole sections of the same blocks. The microarrays were constructed in the histology laboratory as part of the usual daily workflow. Once a routine process was established, histotechnologists who had mastered the technique produced high-quality arrays with minimal disruption of workflow. The results of this study indicate that, in properly selected cases, the TMA method is a valid option to whole section analysis of breast biomarkers. As a result of this study, the BCCA laboratory has commenced routine analysis of breast biomarkers using the TMA method.
A very conservative protocol that required 4 cores per case for the TMA was used in this study. With this limitation, not all tissue samples were suitable for TMA. Only 45% of the consented cases had sufficient invasive carcinoma to allow 4-core sampling and still leave useful clinical tumor in the block. Core needle biopsy cases represented 55.7% of the rejected cases. Adding cores extracted from breast needle core biopsies was considered for this study, but issues of tissue adequacy and fixation variables would have added further complexity to the number of preanalytic variables. Thus, breast core biopsies were excluded from this study. The remainder of the excluded cases were small biopsy specimens with insufficient tumor tissue (18.4%), ductal carcinoma in situ (DCIS) only, or DCIS with microinvasive carcinoma (25.9%).
There was a high retention rate of informative cores in the arrays with only a 1.7% loss of cores, similar to what was reported in another study of clinical TMA use. 5 Of the cores, 7% had no tumor, probably reflecting an overzealous attempt to capture both central and peripheral tumor, with the peripheral cores missing the tumor in the block. Subsequent clinical use of this method has found that core loss and noninformative core sampling are lower than reported in this study (data not shown).
Valid results can be obtained with fewer than 4 cores. Statistical analysis revealed that even 2 core samples could potentially yield similar results to a 4-core sample ( Table 7) . The adequacy of a limited number of cores has been previously reported. 9, 10 In the subsequent clinical implementation of the TMA method, to ensure adequate cores are available for analysis, a 3-core array protocol has been adopted for clinical work. This approach has allowed about 50% of biomarker cases to be processed by TMA.
Interobserver variability was not significant for PR and HER2 at 4 levels of intensity. Only ER, while interpreted at 4 levels of intensity, showed a significant difference in interobserver analysis. However, when ER was interpreted using the more clinically relevant stain threshold of stained nuclei present (positive) vs no stained nuclei present (negative), no statistically significant difference was found.
With multiple core samples, there are several possible ways to interpret the immunohistochemical biomarker results. Four options were assessed: the maximum stain of 4 cores; the mean intensity of 4 cores; the maximum percentage of stained cells of 4 cores; and the mean of the score derived from a combination of percentage of stained cells and maximum intensity (similar to the UK Quick score or the Allred score) of the 4 cores. Analysis revealed that the maximum stain intensity in 1 core gave the highest concordance with the reported result on whole section. This was true for all antibodies, and, therefore, this method was adopted for the study and subsequent clinical use.
Sampling issues are a significant concern in the use of TMA. At present in this laboratory, the threshold for calling a case ER+ or PR+ is the presence of any nuclear staining. This low threshold increases the risk of sampling error because rare positive nuclei present in a whole section may not be sampled with the TMA cores. In 2% of ER cases, the ER on TMA was falsely negative owing to failure to sample focal areas of positively stained nuclei revealed only on whole section. This finding indicates it is prudent to repeat all ER-TMA cases on whole section to capture these occasional false-negative cases. A similar observation and conclusion were noted in a previous report on the use of TMA for clinical work. 5 The study indicated it cannot be assumed that the staining protocol used on whole sections will be suitable for TMA staining for all antibodies. The variable antibody concordance indicates the need to validate each antibody independently. The concordance results of antibody stains between whole sections and TMAs using the same staining protocol for ER and PR were high, yet this was not the case for HER2. The initial protocol for the Ventana 4B5 antibody on whole sections recommended by the supplier was oversensitive, as revealed by an excess of false-positive HER2 results compared with amplification status by FISH in whole sections and TMAs. After completion of the study, the staining protocols for TMAs and whole sections were optimized to achieve satisfactory concordance with FISH. By using the optimized staining protocols for whole sections and TMAs, current concordance in the laboratory on TMA of immunohistochemical analysis with the Ventana 4B5 antibody as compared with FISH exceeds 95%, as recommended by recent guidelines. 11 
